Back to results
US 8,273,763 B2Granted
Drugs for the treatment of sarcoglycanopathies
AssigneesGenethon, Centre National De La Recherche Scientifique
InventorIsabelle Richard
Life of this patent
Estimating the term…
Abstract
Inhibitors of the endoplasmic reticulum associated degradation (ERAD) pathway, particularly inhibitors of mannosidase I, are used to treat sarcoglycanopathies.
Claims6
A method of treating a sarcoglycanopathy comprising administering to a subject in need of such treatment a therapeutically effective amount of a class I α-mannosidase inhibitor, wherein said inhibitor comprises kifunensin or 1-deoxymannojirimycin.
Dependencies are inferred from the claim text.